It seems that the Blue House officials took the lead in attracting Pfizer vaccine consignment production and failed because they were pushed by China.
Fuxing Pharmaceuticals, a subsidiary of China's Fuxing Pharmaceutical Group, announced on the 9th that it was a joint venture (joint venture) between Bioentech in Germany, but Samsung Biologics announced on the 12th that it was not true of the Korean media report for vaccine production. .
On the 12th, Pfizer Pharmaceuticals Korea officially announced to some media by government officials that, "As a result of the company's confirmation, we have not discussed local manufacturing other than our own production."
Pfizer's subsidiary, Korea Pfizer Korea, reported that the official remarks of the Korean media continued. "As a result of checking with the global headquarters, it is an official position that local manufacturing is not considered considering the uniqueness of the mRNA vaccine technology and the quality when manufactured externally." 12 Sun said final.
On the basis of the fact that a Korean official said on the 11th that “Samsung Biologics is laying facilities for Pfizer vaccine production at Incheon's Songdo 3 plant,” the Korea Economic Daily reported on the 11th < As early as August, Samsung Biologics will consign a COVID-19 vaccine from Pfizer, a US pharmaceutical company.
This is the result of a “big deal” between Pfizer's COVID-19 vaccine technology and Samba's mass production capability, which has established itself as the global No. 1 pharmaceutical consignment manufacturing (CMO) company. Samba's annual production of Pfizer vaccine is at least 1 billion doses (500 million people).
Pfizer's vaccine co-developer, the German Bioentech Research Institute, announced the production and distribution of vaccines in Hong Kong, Macau, and Taiwan in partnership with Pfizer in the United States, and announced “the prospect of approval by the Chinese health authorities until July” from April. The communication reported.
BioEntech Research Institute announced last month that it is producing and distributing vaccines in Hong Kong, Macau, and Taiwan through partnership with US pharmaceutical company Pfizer, and it is expected to obtain approval from Chinese health authorities by July at the latest.
The share price of Samsung Biologics has risen greatly in the possibility of Pfizer's consignment production of the Corona 19 vaccine. However, the company announced "it is not true," and began to be wary of premature speculation.
South Korea's share price rose 39,000 won (4.77%) to 856,000 won despite Samsung's wife's remarks in the stock market on the 12th due to the official's remarks to attract Samba. Samba, which rose from the 3rd as a result of officials' comments on the production of Pfizer vaccines in Korea, surged more than 10% to Samba's official wife from 771,000 won a week ago.
Samba stocks surged 6% due to psychological warfare on the 12th. Partnership," said "The US has the original technology and raw materials for vaccines, and Korea has the world's second-class bio-production capacity," contributing to the share price hike.
As for the mRNA vaccine, which is the issue of Pfizer's stock stimulus, development and production countries were limited to the United States and Germany, and China announced the establishment of a subsidiary vaccine factory. In discussions with pharmaceutical companies,” he said, stimulating the share price rise.
On the 7th, when related stocks began to rise, Kwon Joon-wook, head of the 2nd vice president of the Korea Centers for Disease Control and Prevention, said in a regular briefing, "The mRNA vaccine platform is a technology that can be extended to other chronic diseases other than infectious diseases such as cancer, so it must be secured."
The mRNA vaccine is a new technology that induces an immune response by injecting an antigen gene in the form of mRNA, and it was first commercialized in the corona crisis and is known to be useful for mutant viruses.
“Media Today,” he said, saying, “The source of information is “high-ranking government officials”. “Samsung Biologics is setting up facilities for Pfizer vaccine production at its 3rd plant in Songdo, Incheon,” and “It is possible to enter mass production from August,” said an anonymous reporter. “The Korean economy is'very friendly to Samsung'.” In connection with the January report on'Lee Jae-yong's Special Vaccine Special Issue', the report was pointed out as a typical'Samsung side' report that praised'Lee Kun-hee's last gift' for the announcement of the heritage inheritance plan.> It was revealed that the remarks were covered.
Whether or not the officials have provided the media with a judgment on “contracting” by saying “the facility is being installed”, and whether the media independently judged the “contract” only by saying facility statements, the issue of determining the actual stock price manipulator is the issue.
As the controversy grows on Pfizer Korea, the “Korea Economy” reported on the 12th, “Samsung Bio denies Pfizer vaccine production…” The report on May 12, which contained the content of consignment production of the Pfizer vaccine, titled "Vaccine Cooperation Discussion at the Korea-US Summit", was denied. However, the industry still sees a high possibility that Samba will consign a vaccine to a global pharmaceutical company.>
Pfizer Korea, whose headquarter is A, said on the 12th, "As a result of stock-related issues, Pfizer Korea, who is headquartered in Pfizer, confirmed with the global headquarters that it is an official position that local manufacturing is not considered considering the uniqueness of the mRNA vaccine technology and the quality when manufactured externally." It has avoided signing a joint venture with Germany's Bioentech and China's Fuxing Pharmaceuticals.